Which company manufactures Trientine?

Trientine (Trientine) is a chelate drug developed by pharmaceutical companies such as Pharmaxis in the United States and Univar Solutions in the United Kingdom. Its most representative original drug is from an American company with the trade name Syprine. In addition, the British company Orphalan also produces and sells a similar original drug under the trade name Cufence. Both are the original brands of trientine that are widely used around the world and have been approved by the US FDA and the European EMA for long-term copper excretion treatment in patients with Wilson's disease.

The trientine produced by these companies mainly exists in the form of trientine dihydrochloride or trientine tetrahydrochloride. It is a second-generation copper chelator and is usually used as an alternative option for patients who fail or are intolerant to penicillamine treatment.

In addition, generic versions of trientine have been developed in recent years to meet the clinical needs of developing countries. Although the active ingredients of these generic drugs are consistent with the original drugs, some products have not yet been certified by the U.S. Food and Drug Administration (FDA) or China's National Medical Products Administration (NMPA), and therefore still require strict supervision in terms of drug quality consistency and stability.

The production process of trientine is relatively complex, involving the synthesis of high-purity chelate structures and humidity control technology, and the stability of its preparation directly affects the efficacy. Therefore, major pharmaceutical companies around the world optimize production processes through patented technologies to ensure the long-term stability and safety of drugs. In the future, with Wilson's disease being included in China's list of rare diseases and related policy support, local pharmaceutical companies may cooperate with foreign original research companies to introduce trientine preparations, significantly improving the accessibility of this important drug in the Chinese market.

Reference materials:https://www.cufence.com/